Trials / Unknown
UnknownNCT05928897
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study (DVES)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study
Detailed description
We initiated the efficacy and safety of the first Disitamab Vedotin combined with Sintilimab in second-line therapy in patients with advanced gastric cancer with positive HER2 or low expression of HER2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Disitamab Vedotin combined with Sintilimab | Disitamab Vedotin combined with Sintilimab |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2023-07-03
- Last updated
- 2023-07-05
Source: ClinicalTrials.gov record NCT05928897. Inclusion in this directory is not an endorsement.